BioSpaceOriginal article
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
Data ReadoutpositiveKyverna CAR TPositive
AI Analysis
Summary
Kyverna Therapeutics reported positive data for its CAR T cell therapy for autoimmune disease, positioning it as a potential first-to-market treatment in this indication amid ongoing safety discussions following deaths in Novartis' autoimmune CAR T trials.
Outcome Details
Kyverna reported data supporting CAR T for autoimmune disease indication
Importance:6/10
Sentiment:
0.60
CAR Tautoimmune diseaseregulatory pathwayclinical datafirst-in-class potentialsafety concerns
Read the original article
Published by BioSpace on October 5, 2026 4:44 AM